Boston-based CORE Biomedicine launched with USD 21 million in Series A financing, an award from Japan's Agency for Medical Research and Development (AMED), and exclusive global rights to a portfolio of preclinical oncology programs licensed from Japan-based Eisai Co., Ltd. (TYO: 4523), giving the newly formed company an immediate pipeline built on assets originating from a major pharmaceutical company. Financial terms of the licensing agreement were not disclosed.
The licensed portfolio comprises multiple preclinical oncology programs discovered through Eisai's internal research operations and targeting distinct molecular drivers across several biological pathways. While neither company disclosed the specific targets or therapeutic modalities, CORE said its scientific strategy is centered on lineage biology and cancer cell differentiation, with the aim of developing precision medicines that address fundamental drivers of tumor identity beyond conventional genomic alterations.
The simultaneous financing, licensing agreement and AMED grant suggest the company was established around the Eisai portfolio rather than adding external assets to an existing pipeline. CORE will assume responsibility for global development and commercialization of the licensed programs as it advances them toward the clinic. The company operates across the US, Japan and China, reflecting the cross-border origins of both its scientific platform and investor base.
The arrangement is an uncommon example of a large pharmaceutical company providing the founding assets for a newly created biotechnology company. Rather than acquiring innovation from an emerging biotech, Eisai has transferred a portfolio of internally discovered programs into an independent venture backed by external financing. Similar structures have occasionally been used to advance programs that fall outside a pharmaceutical company's strategic priorities while allowing development to continue under a dedicated management team, although such transactions remain relatively uncommon.